Physiologically based pharmacokinetic models for everolimus and sorafenib in mice

PURPOSE: Everolimus is a mammalian target of rapamycin (mTOR) inhibitor approved as an immunosuppressant and for second-line therapy of hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC). Sorafenib is a multikinase inhibitor used as first-line therapy in HCC and RCC. This study assessed t...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Pawaskar, Dipti K., Straubinger, Robert M., Fetterly, Gerald J., Hylander, Bonnie H., Repasky, Elizabeth A., Ma, Wen W., Jusko, William J.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2013
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC3755750/
https://ncbi.nlm.nih.gov/pubmed/23455451
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-013-2116-y
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन